搜索
Mediwound Ltd
MDWD添加自选
16.410USD
-0.385-2.29%
收盘 05/15, 16:00（美东）报价延迟15分钟
210.91M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.29%
5天
-0.97%
1月
-4.04%
6月
-10.08%
今年开始到现在
-11.11%
1年
-19.87%
TradingKey Mediwound Ltd股票评分
单位: USD 更新时间: 2026-05-15操作建议
Mediwound Ltd当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在药品行业排名86/155位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价31.00。中期看，股价处于平稳状态。近一个月，市场表现较差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Mediwound Ltd评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Mediwound Ltd亮点
亮点风险
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
业绩增长期
公司处于发展阶段，最新年度总收入16.96M美元
利润高增长
公司净利润处于行业前列，最新年度总收入16.96M美元
估值合理
公司最新PE估值-7.82，处于3年历史合理位
机构加仓
最新机构持股7.42M股，环比增加3.86%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值5.59K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.34
分析师目标
根据
6
位分析师
买入
评级
31.000
目标均价
+84.58%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Mediwound Ltd新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Mediwound Ltd简介
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
公司代码MDWD
公司Mediwound Ltd
CEOGonen (Ofer)
网址https://www.mediwound.com/
相关品种
